XML 78 R67.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2017 | Mar. 31, 2016
Segment Reporting Information [Line Items] |  |
Sales | $ 9,434 | $ 9,312
Proceeds from sale of marketing rights | 50 | 75
corticotropin marketing rights |  |
Segment Reporting Information [Line Items] |  |
Proceeds from sale of marketing rights |  | 75
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 9,218 | 9,009
Operating Segments | Total Pharmaceutical segment sales |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,185 | 8,104
Operating Segments | Total Pharmaceutical segment sales | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 334 | 612
Operating Segments | Total Pharmaceutical segment sales | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 241 | 277
Operating Segments | Total Pharmaceutical segment sales | Liptruzet |  |
Segment Reporting Information [Line Items] |  |
Sales | 49 | 23
Operating Segments | Total Pharmaceutical segment sales | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 84 | 33
Operating Segments | Total Pharmaceutical segment sales | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 839 | 906
Operating Segments | Total Pharmaceutical segment sales | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 496 | 506
Operating Segments | Total Pharmaceutical segment sales | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 170 | 134
Operating Segments | Total Pharmaceutical segment sales | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 160 | 175
Operating Segments | Total Pharmaceutical segment sales | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 81 | 94
Operating Segments | Total Pharmaceutical segment sales | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 378 | 50
Operating Segments | Total Pharmaceutical segment sales | Isentress |  |
Segment Reporting Information [Line Items] |  |
Sales | 305 | 340
Operating Segments | Total Pharmaceutical segment sales | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 148 | 90
Operating Segments | Total Pharmaceutical segment sales | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 141 | 145
Operating Segments | Total Pharmaceutical segment sales | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 136 | 114
Operating Segments | Total Pharmaceutical segment sales | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 121 | 133
Operating Segments | Total Pharmaceutical segment sales | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 96 | 292
Operating Segments | Total Pharmaceutical segment sales | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 62 | 73
Operating Segments | Total Pharmaceutical segment sales | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 229 | 349
Operating Segments | Total Pharmaceutical segment sales | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 184 | 188
Operating Segments | Total Pharmaceutical segment sales | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 584 | 249
Operating Segments | Total Pharmaceutical segment sales | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 133 | 126
Operating Segments | Total Pharmaceutical segment sales | Temodar |  |
Segment Reporting Information [Line Items] |  |
Sales | 66 | 66
Operating Segments | Total Pharmaceutical segment sales | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 186 | 237
Operating Segments | Total Pharmaceutical segment sales | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 139 | 229
Operating Segments | Total Pharmaceutical segment sales | Dulera |  |
Segment Reporting Information [Line Items] |  |
Sales | 82 | 113
Operating Segments | Total Pharmaceutical segment sales | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 112 | 126
Operating Segments | Total Pharmaceutical segment sales | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 103 | 111
Operating Segments | Total Pharmaceutical segment sales | Fosamax |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 75
Operating Segments | Total Pharmaceutical segment sales | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 532 | 378
Operating Segments | Total Pharmaceutical segment sales | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 355 | 357
Operating Segments | Total Pharmaceutical segment sales | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 224 | 188
Operating Segments | Total Pharmaceutical segment sales | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 163 | 107
Operating Segments | Total Pharmaceutical segment sales | Zostavax |  |
Segment Reporting Information [Line Items] |  |
Sales | 154 | 125
Operating Segments | Total Pharmaceutical segment sales | Other Pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,037 | 1,083
Operating Segments | Other segment sales |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,033 | 905
Other |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 216 | $ 303

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CorticotropinmarketingrightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_LiptruzetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_IsentressMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_GardasilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |